Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation

Dave Singh; Leonardo M Fabbri; Massimo Corradi; George Georges; Alessandro Guasconi; Stefano Vezzoli; Stefano Petruzzelli; Alberto Papi

doi:10.1183/13993003.00235-2019

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation

Eur Respir J. 2019 May 18;53(5):1900235. doi: 10.1183/13993003.00235-2019. Print 2019 May.

Authors

Dave Singh¹, Leonardo M Fabbri^{2

3}, Massimo Corradi⁴, George Georges⁵, Alessandro Guasconi⁶, Stefano Vezzoli⁶, Stefano Petruzzelli⁶, Alberto Papi²

Affiliations

¹ Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK [email protected].
² Section of Cardiorespiratory and Internal Medicine, Dept of Medical Sciences, University of Ferrara, Ferrara, Italy.
³ COPD Center, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
⁴ Dept Medicine and Surgery, University of Parma, Parma, Italy.
⁵ Global Clinical Development, Chiesi USA, Inc., Cary, NC, USA.
⁶ Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.

Abstract

In patients with symptomatic COPD, severe/very severe airflow limitation, and a history of one moderate (and no severe) exacerbation, ICS-containing triple therapy significantly reduces exacerbation risk overall versus single or double maintenance therapy http://ow.ly/VgJC30o9pXC

Publication types

Comparative Study
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Inhalation
Beclomethasone / administration & dosage*
Bronchodilator Agents / administration & dosage*
Drug Combinations
Forced Expiratory Volume
Formoterol Fumarate / administration & dosage*
Glycopyrrolate / administration & dosage*
Humans
Pulmonary Disease, Chronic Obstructive / drug therapy*
Treatment Outcome

Substances

Bronchodilator Agents
Drug Combinations
Beclomethasone
Glycopyrrolate
Formoterol Fumarate